Clinical Trials
9 trialsNCT03218826 2026-04-29
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02834403 2023-12-15
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT01920061 2022-09-13
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Phase 1 Completed
NCT03154749 2022-09-01
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT02413320 2021-05-10
NeoSTOP
University of Kansas Medical Center
Phase 2 Completed
NCT01216111 2020-05-19
Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)
Fudan University
Phase 3 Completed
NCT01208480 2012-04-10
Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer
Severance Hospital
Phase 2 Completed